clinical trial · NCT07650084
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
Refractory Chronic CoughBLU-5937Placebo
brief summary
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
started
Nov 21, 2025
primary completion
Aug 27, 2027
completion
Jun 2, 2028
last updated
Jun 16, 2026
detailed description
The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained chronic cough) at 24 weeks.
official title
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2) - China Extension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol